Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sensinnovat is a private Belgian family holding and investment company rather than a drug-development biotech, pharma, or healthcare operating company. Publicly available sources describe it as an active investor in high-tech startups and initiatives intended to improve quality of life and sustainability. The entity appears to be controlled by Rudi De Winter and Françoise Chombar and has been disclosed in Belgian shareholder notifications related to holdings in public companies such as Sequana Medical. Its activity is best characterized as strategic investing and portfolio management, including some exposure to health-tech or medical-device investments, not internal therapeutic R&D.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sensinnovat.